Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
JCO Precision Oncology|February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerCharu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2004
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R)Enkhtsetseg Purev, Dewei Cai, Eric Miller, et al.Investigational New Drugs|April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.Plos One|August 7, 2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyGeorge J Cerniglia, Nabendu Pore, Jeff H Tsai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersErica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2024
FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced MelanomaThomas M Anderson, Bryan H Chang, Alexander C Huang, et al.Cancer Research|November 3, 2007
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillanceSusan M Domchek, Adri Recio, Rosemarie Mick, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2021
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A Reiss, Rosemarie Mick, Mark H O'Hara, et al.Oral Oncology|February 12, 2016
Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumorsPeter H Ahn, Harry Quon, Bert W O'Malley, et al.Oncoimmunology|October 10, 2015
Progressive loss of anti-HER2 CD4<sup>+</sup> T-helper type 1 response in breast tumorigenesis and the potential for immune restorationJashodeep Datta, Cinthia Rosemblit, Erik Berk, et al.Pageof 12